The purpose of the public hearing is to obtain public input on the state of the science regarding FMT to treat C. difficile infection not responsive to standard therapies, including the available clinical evidence for safety and effectiveness of FMT for this use and to better understand the impact of FDA’s enforcement policy on product development.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2nRff4k
No comments:
Post a Comment